Drug intelligence / Profile preview

Vera Salus Ricerca IBD small molecule

Development stage: Preclinical
Lead developer: Vera Salus Ricerca
Modality: Small Molecules

Overview

This preclinical small-molecule candidate is being developed by Vera Salus Ricerca for the treatment of Inflammatory Bowel Diseases (IBD). The therapy specifically targets the intestinal mucosal barrier, aiming to restore its integrity and protective function. In IBD, the breakdown of this barrier allows for the translocation of luminal antigens, triggering chronic inflammation. By reinforcing the mucosal lining, this drug candidate seeks to provide a novel therapeutic approach to managing conditions like Crohn's disease and ulcerative colitis. The program is currently in the preclinical stage of development.

Beyond the preview

Go deeper on Vera Salus Ricerca IBD small molecule.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vera Salus Ricerca IBD small molecule.

Explore the full profile